 <h1>Ocrelizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ocrelizumab include:</b> lower respiratory tract infection, upper respiratory tract infection, cough, and infusion related reaction.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ocrelizumab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ocrelizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ocrelizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>chest tightness</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>ear congestion</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>feeling of warmth</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, or skin rash</li>
<li>loss of voice</li>
<li>nausea</li>
<li>pain, redness, swelling, tenderness, or warmth on the skin</li>
<li>rapid weight gain</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sweating</li>
<li>tingling of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning or stinging of the skin</li>
<li>painful blisters on the trunk of the body</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Eye pain or redness</li>
<li>mental changes</li>
<li>stiff neck</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ocrelizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ocrelizumab: intravenous solution</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)</p>
<p><b>Common</b> (1% to 10%): Bronchitis, cough<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Breast cancer<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, pain in extremity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion reactions (40%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Herpes virus associated infections</p>
<p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutrophil levels decreased (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin infections (14%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Peripheral edema<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ocrevus (ocrelizumab)." Genentech, South San Francisco, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>How much does an Ocrevus infusion cost?</li>
<li>Is Ocrevus a form of chemotherapy?</li>
<li>How long does it take Ocrevus to work?</li>
<li>How does Ocrevus work for MS?</li>
<li>How long does an Ocrevus infusion take?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about ocrelizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>107 Reviews</li>
<li>Drug class: CD20 monoclonal antibodies</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ocrelizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Ocrevus</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ocrelizumab: intravenous solution</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)</p><p><b>Common</b> (1% to 10%): Bronchitis, cough<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Breast cancer<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, pain in extremity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion reactions (40%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Herpes virus associated infections</p><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutrophil levels decreased (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin infections (14%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Peripheral edema<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ocrevus (ocrelizumab)." Genentech, South San Francisco, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs used for multiple sclerosis (MS)?</li>
<li>How much does an Ocrevus infusion cost?</li>
<li>Is Ocrevus a form of chemotherapy?</li>
<li>How long does it take Ocrevus to work?</li>
<li>How does Ocrevus work for MS?</li>
<li>How long does an Ocrevus infusion take?</li>
</ul><h2>More about ocrelizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>107 Reviews</li>
<li>Drug class: CD20 monoclonal antibodies</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ocrelizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Sclerosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>